Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Expert Opinion on Therapeutic Targets|January 31, 2006
The small-molecule immune response modifier imiquimod--its mode of action and clinical use in the treatment of skin cancerMichael P Schön, Margarete Schön
Current Medicinal Chemistry|March 10, 2007
The antitumoral mode of action of imiquimod and other imidazoquinolinesMargarete Schön, Michael P Schön
The Journal of Investigative Dermatology|April 1, 2006
The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashionMichael P Schön, Margarete Schön, Karl-Norbert Klotz
Lancet (London, England)|June 12, 2002
Reliability of diagnosis of melanoma in situMosaad Megahed, Margarete Schön, Dennis Selimovic, et al.
The Journal of Investigative Dermatology|August 16, 2005
Expression of gp130 in tumors and inflammatory disorders of the skin: formal proof of its identity as CD146 (MUC18, Mel-CAM)Margarete Schön, Thilo Kähne, Harald Gollnick, et al.
Experimental Dermatology|February 17, 2016
Integrin αE (CD103) is induced but plays no pathogenic role in psoriasiform skin lesions of TGFβ1 transgenic miceAndrea Braun, Stephanie Schlickum, Nadin Dewert, et al.
Experimental Dermatology|November 3, 2011
Stimulation of pulmonary immune responses by the TLR2/6 agonist MALP-2 and effect on melanoma metastasis to the lungTillmann Schill, Michael P Schön, Nadin Pletz, et al.
The Journal of Investigative Dermatology|September 4, 2009
Inhibition of platelet GPIb alpha and promotion of melanoma metastasisLuise Erpenbeck, Bernhard Nieswandt, Margarete Schön, et al.
The Journal of Investigative Dermatology|November 27, 2009
NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathwaysKatharina Amschler, Michael P Schön, Nadin Pletz, et al.
Experimental Dermatology|February 11, 2012
Doxorubicin-induced activation of NF-κB in melanoma cells is abrogated by inhibition of IKKβ, but not by a novel IKKα inhibitorNadin Pletz, Margarete Schön, Karl Ziegelbauer, et al.
Pageof 3